A detailed history of Fort Sheridan Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fort Sheridan Advisors LLC holds 2,038 shares of VRTX stock, worth $919,076. This represents 0.15% of its overall portfolio holdings.

Number of Shares
2,038
Previous 2,027 0.54%
Holding current value
$919,076
Previous $950,000 0.32%
% of portfolio
0.15%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $5,060 - $5,563
11 Added 0.54%
2,038 $947,000
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $138,269 - $170,906
352 Added 21.01%
2,027 $950,000
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $78,684 - $86,093
-193 Reduced 10.33%
1,675 $700,000
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $106,494 - $121,485
376 Added 25.2%
1,868 $588,000
Q2 2022

Aug 08, 2022

BUY
$234.96 - $292.55 $82,705 - $102,977
352 Added 30.88%
1,492 $421,000
Q1 2022

May 09, 2022

SELL
$221.42 - $260.97 $35,648 - $42,016
-161 Reduced 12.38%
1,140 $298,000
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $230,290 - $290,708
1,301 New
1,301 $286,000
Q2 2021

Aug 17, 2021

SELL
$187.49 - $221.1 $215,800 - $254,486
-1,151 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $142,636 - $166,262
-689 Reduced 37.45%
1,151 $247,000
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $380,898 - $508,005
1,840 New
1,840 $435,000
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $178,955 - $212,170
-700 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $157,836 - $207,060
700 New
700 $203,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Fort Sheridan Advisors LLC Portfolio

Follow Fort Sheridan Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fort Sheridan Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fort Sheridan Advisors LLC with notifications on news.